Results 161 to 170 of about 37,220 (200)

Detection of BRAF V600E mutation by pyrosequencing

Pathology, 2008
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of hereditary non-polyposis colorectal cancer (Lynch's syndrome) and for the prediction of sensitivity to MEK inhibitors. Here we describe a method for detecting this mutation based upon pyrosequencing technology.The efficiency of pyrosequencing for detecting
Tan, Y.H., Salto-Tellez, M., Soong, R., Liu, Y., Eu, K.W., Ang, P.W., Li, W.Q., Iacopetta, B.   +7 more
openaire   +3 more sources

Dabrafenib in advanced melanoma with BRAF V600E mutation

The Journal of Community and Supportive Oncology, 2014
Dabrafenib was recently approved by the US Food and Drug Administration for treatment of unresectable or metastatic melanoma with BRAF V600E mutations as detected by an FDA-approved test. The THxID BRAF assay, for detection of BRAF V600E mutations was concurrently approved.
Jame, Abraham, Matt, Stenger
openaire   +2 more sources

Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas

Clinical Oral Investigations, 2018
This study aimed to investigate the presence of BRAF V600E mutation in mandible ameloblastomas by correlating clinical and imaging data on the cases studied.Eighty-four cases diagnosed as mandibular ameloblastoma were selected for analysis. The specimens were submitted to immunohistochemistry for detection of BRAF V600E mutated protein.
Alan Motta do Canto, Barbara Michaela Reis da Silva Marcelino, Juliana Lucena Schussel, Bruna F. Wastner, Laurindo Moacir Sassi, Luciana Corrêa, Ronaldo Rodrigues de Freitas, Bengt Hasséus, Göran Kjeller, Celso Augusto Lemos Junior, Paulo Henrique Braz-Silva   +10 more
openaire   +2 more sources

The Histopathology of BRAF-V600E–mutated Lung Adenocarcinoma

American Journal of Surgical Pathology, 2008
BRAF mutations in lung adenocarcinoma are much less common than the more frequently reported and mutually exclusive mutations of KRAS and EGFR genes, and the clinical and histologic phenotype of BRAF adenocarcinomas has not been described. We analyzed 222 adenocarcinomas of lung lacking KRAS and EGFR mutations and identified 10 adenocarcinomas with ...
Samuel A, Yousem, Marina, Nikiforova, Yuri, Nikiforov   +2 more
openaire   +2 more sources

Targeting the BRAF V600E Mutation in Multiple Myeloma

Cancer Discovery, 2013
Abstract In multiple myeloma, there has been little progress in the specific therapeutic targeting of oncogenic mutations. Whole-genome sequencing data have recently revealed that a subset of patients carry an activating mutation (V600E) in the BRAF kinase.
Mindaugas, Andrulis, Nicola, Lehners, David, Capper, Roland, Penzel, Christoph, Heining, Jennifer, Huellein, Thorsten, Zenz, Andreas, von Deimling, Peter, Schirmacher, Anthony D, Ho, Hartmut, Goldschmidt, Kai, Neben, Marc S, Raab   +12 more
openaire   +2 more sources

Absence of the BRAF V600E mutation in pheochromocytoma

Journal of Endocrinological Investigation, 2015
Pheochromocytomas (PCCs) are rare endocrine tumors originating from the adrenal medulla. These tumors display a highly heterogeneous mutation profile, and a substantial part of the causative genetic events remains to be explained. Recent studies have reported presence of the activating BRAF V600E mutation in PCC, suggesting a role for BRAF activation ...
Johan O, Paulsson, F, Svahn, J, Welander, L, Brunaud, P, Söderkvist, O, Gimm, A, Stenman, C C, Juhlin   +7 more
openaire   +2 more sources

Braf V600E mutation in melanoma: translational current scenario

Clinical and Translational Oncology, 2016
Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity.
J A, Guadarrama-Orozco, A, Ortega-Gómez, E B, Ruiz-García, H, Astudillo-de la Vega, A, Meneses-García, C, Lopez-Camarillo   +5 more
openaire   +2 more sources

BRAF (V600E) mutation in isthmic malignant thyroid nodules

Clinical Endocrinology, 2015
Thyroid cancers occur in approximately 2-5% of all nodules, with an incidence of about 3.8% of all new cancer diagnosis in 2014. Differentiated thyroid cancer (DTC) is the most common thyroid cancer type. Incidence has been increasing in the last few decades, mainly due to incidental detection of small, low-risk, cancers (i.e.
CAMPENNI', Alfredo, Giovanella, L, ALIBRANDI, Angela, SIRACUSA, MASSIMILIANO, RUGGERI, Rosaria Maddalena, BALDARI, Sergio   +5 more
openaire   +3 more sources

Somatic BRAF-V600E Mutations in Familial Colorectal Cancer

Cancer Epidemiology, Biomarkers & Prevention, 2006
Abstract The BRAF gene is mutated in 4% to 12% of unselected colorectal cancers, particularly those with high microsatellite instability and in premalignant lesions, such as serrated adenomas and hyperplastic polyps. However, it has been shown that activating BRAF mutations are almost never found in tumors from hereditary nonpolyposis ...
Jana, Vandrovcova, Kristina, Lagerstedt-Robinsson, Lars, Påhlman, Annika, Lindblom   +3 more
openaire   +2 more sources

Desmoplastic non-infantile astrocytic tumor with BRAF V600E mutation

Brain Tumor Pathology, 2014
[Abstract not Available]
Karabagli, Pinar, Karabagli, Hakan, Kose, Dogan, Kocak, Nadir, Etus, Volkan, Koksal, Yavuz   +5 more
openaire   +4 more sources